Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma. (16th March 2019)

• Record Type: Journal Article
• Authors: Luwor, Rodney; Morokoff, Andrew P.; Amiridis, Stephanie; D'Abaco, Giovanna; Paradiso, Lucia; Stylli, Stanley S.; Nguyen, Hong P. T.; Tarleton, Mark; Young, Kelly A.; O'Brien, Terence J.; Robinson, Phillip J.; Chircop, Megan; McCluskey, Adam; Jones, Nigel C.
• Is Part Of: Cancer investigation. Volume 37:Number 3(2019)
• Page Start: 144
• Page End: 155
• Publication Date: 2019-03-16
• Subjects: Glioblastoma -- Cancer stem cells -- Dynamin -- Cancer biology -- Invasion; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2019.1582060
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: Glioma stem cells (GSCs) play major roles in drug resistance, tumour maintenance and recurrence of glioblastoma. We investigated inhibition of the GTPase dynamin 2 as a therapy for glioblastoma. Glioma cell lines and patient-derived GSCs were treated with dynamin inhibitors, Dynole 34-2 and CyDyn 4-36. We studied about cell viability, and GSC neurosphere formation in vitro and orthotopic tumour growth in vivo . Dynamin inhibition reduced glioblastoma cell line viability and suppressed neurosphere formation and migration of GSCs. Tumour growth was reduced by CyDyn 4-36 treatment. Dynamin 2 inhibition therefore represents a novel approach for stem cell-directed Glioblastoma therapy.